

The proposed agenda for the May 2023 CPT Editorial Panel meeting shows the code application names, code(s) affected, and a description of the request. The Code Numbers and Request Descriptions detailed in this document are extracted from Code Applications submitted for discussion at this meeting. **Until such** time as the CPT Editorial Panel acts on these requests, the information that appears in this Proposed Agenda is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).

Codes that contain an 'X' (e.g., 102X4, 2342X, 130XT) below are placeholder codes that are intended, through the first three digits, to give readers an idea of the proposed placement in the code set of the potential code changes. These codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed early September of each year. To report the services for "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed early September of the corresponding year.

NOTICE – INTERESTED PARTY PROCESS

Please note that starting at the February 2023 Panel meeting, non-Pathology issues have a new Interested Party (IP) request process. Please follow the new link below to access the new IP request platform.

Upon review of this agenda, if the non-Advisor reviewer believes that they may want to provide written comments on an application, the reviewer must seek Interested Party status by submitting a request form. The form requires identification of the potential Interested Party, a brief summary of the basis for the request (e.g., associated vendor/ industry representative), and signature of the confidentiality agreement and disclosure of interest forms.

- For Non-Pathology issues, only requests submitted via the CPT Smart App's Interested Party Portal will be considered (new request platform)
- For Path/Lab issues, the request deadline has passed

Any recognized Interested Party who provides written comments must do so no later than the deadlines below and in the Interested Party Portal. Verbal comments can be provided in person at the Panel meeting.

- For Non-Pathology issues, written comments must be submitted via the CPT Smart App's Interested Party Portal
- For Path/Lab issues, written comments must submitted to CPT Staff via email to cptinterestedparties@ama-assn.zendesk.com

| Issues | Tabs | Deadline to Request Materials | Comments Deadline (Noon, CST) |
|--------------------------|-------------------|-------------------------------|-------------------------------|
| All Non-Pathology Issues | 6-9, 11-16, 28-63 | April 13, 2023 | April 20, 2023 |
| Path/Lab | 10, 17-27 | March 3, 2023 | March 6, 2023 |



During the time between now and the Panel meeting, the agenda will more than likely be modified to reflect changes (additions, deletions, or updates). Please check back frequently for the most up to date information. Outcomes on these actions will be found in the CPT Editorial Panel Summary of Actions for the May 2023 meeting which will be published on or before June 2 to the <u>AMA website</u>.

| Tab # | Name | Co | ode# | Request-Description |
|-------|---|----------------------|--------|--|
| | | | | |
| 6 | Critical Care Services | | | WITHDRAWN |
| | | | | |
| 7 | E/M Guidelines Revision - Definition of | | | WITHDRAWN |
| | Discussion | | | |
| 8 | Cat III to Cat I - Health and Well-being | | | Establish codes 99X05 - 99X09 to report health and well-being coaching |
| | Coaching Services | _ | | services; and delete Category III codes 0591T, 0592T, 0593T |
| | | ● 99X07 D | 0593T | |
| | | • 99X09 | | |
| 9 | E/M Guideline Revisions - MDM Table | | | WITHDRAWN |
| | | | | |
| 10 | Cat III 0537T to Cat I - CAR-T Cell Therapy | • 3X018 D (| 0537T | Establish codes 3X018 - 3X022 to report Chimeric Antigen Receptor T Cell |
| | Services | ● 3X019 D (| 0538T | (CAR-T) Services; and delete Category III codes 0537T - 0540T |
| | | ● 3X020 D 0 | 0539T | |
| | | ● 3X021 D (| 0540T | |
| | | ● 3X022 | | |
| 11 | WITHDRAWN | | | |
| | | | | |
| 12 | Intra-Abdominal Tumor Excision or | ● 4X015 D | 49203 | Establish codes 4X015 - 4X019 (open procedure) to describe excision or |
| | Destruction | | | destruction based on the sum of the maximum dimension of all peritoneal, |
| | | ● 4X017 D ● 4X018 | 149205 | mesenteric, and/or retroperitoneal primary or secondary intra-abdominal |

Updated April 28, 2023



| Tab # | Name | | Code # | Request-Description |
|-------|--|----------------|----------------|---|
| | | | | |
| | | • 4X019 | | tumor(s), cyst(s) or endometrioma(s); and delete codes 49203, 49204, 49205 |
| 13 | MRI-Monitored Transurethral US Ablation | ● 5X006 | | Establish codes 5X006, 5X007 to report MRI-monitored transurethral |
| | Prostate | ● 5X007 | | ultrasound ablation of the prostate |
| 14 | Coronary Therapeutic Service Revisions | ● 92X01 | D 92921 | Establish code 92X01 to report percutaneous transluminal |
| | | ▲92920 | D 92925 | revascularization of chronic total occlusion; revise codes 92920, 92924, |
| | | ▲ 92924 | D 92929 | 92928, 92933 ,92937,92941, 92943, 93571 for clarification; and delete |
| | | ▲ 92928 | D 92934 | codes 92921, 92925, 92929, 92934 ,92938, 92944, 92975, 92977 |
| | | ▲92933 | D 92938 | |
| | | ▲92937 | D 92944 | |
| | | ▲92941 | D 92975 | |
| | | ▲92943 | D 92977 | |
| | | ▲93571 | | |
| 15 | Skin Cell Suspension Autograft | ● 15X00 | | Establish codes 15X00 – 15X03 for reporting skin cell suspension autograft; |
| | | ● 15X01 | | and revise the "Autografts/Tissue Cultured Autograft" subheading to only |
| | | ● 15X02 | | state "Autografts" |
| | | ● 15X03 | | |
| 16 | Hand Repair Service Bundling | ● 2X005 | | Establish code 2X005 to report suspension with interposition when |
| | | ▲25447 | | performed; and revise code 25447 by removing the term "interposition" |
| | | | | and adding the phrase "interposition (eg, tendon)" |
| 17 | Acetylcholine Receptor and Muscle Specific | ● 8X036 | | Establish codes 8X036, 8X037, 8X038 to identify testing for Acetylcholine |
| | Kinase Antibody | ● 8X037 | | receptor (AChR) antibodies; and establish code 8X039 to identify testing |
| | | ● 8X038 | | for Muscle specific kinase (MuSK) antibody |
| | | ● 8X039 | | |
| 18 | Cat III-Digital Pathology | ● X139T | • X154T | Establish 30 codes (X139T- X168T) to report additional service |
| | | ● X140T | • X155T | requirements associated with digitizing glass microscope slides for primary |
| | | ● X141T | ● X156T | diagnosis |

Updated April 28, 2023

[▲] Revision



| Tab# | Name | Code # | Request-Description |
|------|---------------------------------------|------------------------------------|---|
| | | | |
| | | - V1 42T V157T | |
| | | ● X142T ● X157T ● X143T ● X158T | |
| | | • X1431 • X1581 • X144T • X159T | |
| | | • X1441 • X1591 • X145T • X160T | |
| | | • X145T • X161T | |
| | | • X147T • X162T | |
| | | • X148T • X163T | |
| | | • X149T • X164T | |
| | | • X150T • X165T | |
| | | • X151T • X166T | |
| | | ● X152T ● X167T | |
| | | ● X153T ● X168T | |
| 19 | MAAA - Colon Cancer-Revise 81528 | ▲81528 | Revise code 81528 to include protein markers |
| | | | |
| 20 | Tier 1-OGM-Constitutional Genome-wide | | WITHDRAWN |
| | Analysis | | |
| - 24 | | | |
| 21 | Tier 1-OGM- Hematologic Malignancy | | WITHDRAWN |
| | | | |
| 22 | Gadolinium Serum Level | ● 8X040 | Request to re-examine the assignment of coding to specifically identify |
| | | | assay of serum gadolinium |
| 23 | Hepatitis D (Delta) Quantitative PCR | ● 8X041 | Establish code 8X041 to identify quantitative detection of Hep D RNA in |
| | | | serum for Hep D virus confirmation |
| 2.4 | Admir AAAAA Caudia | - 00VCN4 | Franklish administrative MAAAA anda COVCAA 1 11 115 11 11 |
| 24 | Admin MAAA-Cardiovascular Disease | ● 00X6M | Establish administrative MAAA code 00X6M to identify residual |
| | | | cardiovascular risk (RCVR) using a multianalyte assay with algorithm |
| | | | cardiovascular risk (RCVR) using a multianalyte assay with algori |



| Tab # | Name | Code # | Request-Description |
|-------|--|---|--|
| | | | |
| 25 | GSP-Matched Normal Sequence Analysis | | WITHDRAWN |
| | Add-on Code | | |
| 26 | Molecular Microbial Resistance | | WITHDRAWN |
| 27 | Ultrasensitive Protein | | WITHDRAWN |
| 28 | Q2 PLA Consent Agenda | | Addition of PLA codes for 2023 Q2 cycle as a consent agenda |
| 29 | Psychotherapy Codes - Revise 90832, 90834, 90837 | | WITHDRAWN |
| 30 | Adaptive Behavior Service Revisions | | WITHDRAWN |
| 31 | Digital Cognitive Behavioral Therapy | | WITHDRAWN |
| 32 | Psychotherapy Duration Codes | ● 90X13 | Establish codes 90X13, 90X14, 90X15 to report psychotherapy duration |
| | | ● 90X14 ● 90X15 | services |
| 33 | mRNA RSV Vaccine | • 9X097 | Establish code 9X097 to report RSV vaccine product, w/ preservative, antibiotic, adjuvant free |
| 34 | Pediatric Healthy Weight Program | 90X0590X0690X07 | Establish codes 90X05 - 90X09 to report pediatric healthy weight program services |



| Tab # | Name | Code # | Request-Description |
|-------|--|--|---|
| | | | |
| | | ● 90X08 | |
| | | • 90X09 | |
| 35 | Prolonged Psychotherapy Services | | WITHDRAWN |
| 36 | Respiratory Syncytial Virus, Pediatric, | • 9X094 | Establish codes 9X094, 9X095 to report use of immune globulin for |
| | Seasonal | ● 9X095 | pediatric protection against respiratory syncytial virus (RSV) |
| 37 | HIPEC Guideline Revisions | | Establish introductory guidelines that describe work that is included in the HIPEC procedures |
| 38 | Transcranial Doppler | +93X94+93X95+93X96▲93893D93890 | Establish add-on codes to report procedures performed with complete transcranial Doppler study of intracranial arteries: vasoreactivity study (93X94), emboli detection without intravenous microbubble injection (93X95), and venous-arterial shunt detection with intravenous microbubble injection (93X96); revise code 93893 to describe venous-arterial shunt detection; and delete code 93890 |
| 39 | Cat III - Noninvasive Artificial Intelligence Classifier | | WITHDRAWN |
| 40 | Cat III - Hybrid SI Joint Fusion - Delete 0809T | D 0809T | Delete code 0809T and provide alternative instruction for reporting hybrid SI joint fusion |
| 41 | TERMINATED | | |
| 42 | Cat III - Percutaneous Nerve Field Stimulation - Revise 0720T | | WITHDRAWN |



| Tab # | Name | Code # | Request-Description |
|-------|--|-------------------------------|--|
| | | | |
| 43 | Cat III - Spectroscopy Study-Wound or Flap - Revise 0640T | ▲ 0640T | Revise code 0640T by removing "of flap or wound" and adding "each site and/or extremity" |
| 44 | Cat III 0042T to Cat I - Computed Tomography Perfusion | ● 7X006 D0042T | Establish code 7X006 to report computed tomography perfusion analysis; and delete code 0042T |
| 45 | Cat III - Opto-Acoustic Imaging for Breast Masses | ● X183T ● X184T | Establish two Category III codes X183T, X184T to report opto-acoustic imaging for breast masses |
| 46 | Cat III - Vascular Embolization with Pressure Modulated Drug Delivery | | WITHDRAWN |
| 47 | Cat III - Percutaneous Coronary Intervention (PCI) by Therapeutic Drug Delivery with Drug-coated Balloon | ● X185T ● X186T ● X187T | Establish codes X185T, X186T, X187T to report percutaneous coronary intervention services |
| 48 | Cat III - Electrophysiological Focused Magnetic Stimulation of Brain | ● X169T | Establish code X169T to report electrophysiologic-focused magnetic subthreshold and low-frequency stimulation measuring brain physiology |
| 49 | Cat III - Quantitative MRI Analysis of Brain with Comparison | ● X188T ● X189T | Establish codes X188T, X189T to report quantitative magnetic resonance image analysis of the brain |
| 50 | Cat III - Near Infrared Spectroscopy (NIRS) for Peripheral Arterial Disease (PAD) | ◆ X171T | Establish code X171T to report noncontact near-infrared spectroscopy for the detection and diagnosis of peripheral arterial disease |
| 51 | Cat III - Capture and Harvest of Circulating Tumor Cells | ● X172T | Establish code X172T to report processing and capture/harvest of circulating tumor cells |
| 52 | Cat III - Prescription Digital Therapeutics | ● X178T ● X179T | Establish codes X178T, X179T to report treatment of inattentive or combined-type attention deficit hyperactivity disorder using digital therapeutic software |



| Tab # | Name | Code # | Request-Description |
|-------|---|--|---|
| | | | |
| 53 | Cat III - Noninvasive Pulmonary Gas Exchange Assessment | ● X173T | Establish code X173T to report measurement of pulmonary gas exchange |
| 54 | Cat III - Peripheral Nerve Transcutaneous Magnetic Stimulation | ▲0766T D0768T D0769T | Revise code 0766T to include each treatment; and delete codes 0768T, 0769T |
| 55 | Cat III - Wireless Cardiac Stimulation System for Left Ventricular Pacing | X180T ▲0517T X181T ▲0518T X182T ▲0519T ▲0520T | Establish codes X180T, X181T, X182T and revise codes 0517T - 0520T to allow more granular reporting of wireless cardiac stimulator components for LV pacing |
| 56 | Cat III - Low Intensity ESWT-Corpus Cavernosum | ● X170T | Establish code X170T to report low intensity extracorporeal low energy shock wave therapy involving the corpus cavernosum |
| 57 | WITHDRAWN | | |
| 58 | Category III Sundown | D0512T D0513T D0533T D0534T D0535T D0536T | Delete Category III codes that are scheduled for sundown in January 2024 |
| 59 | Code Set Maintenance | D34510 D74710 | Delete codes 34510,74710 due to low utilization |
| 60 | Appendix S AI Taxonomy Revisions | | Revise Appendix S-AI Taxonomy to include new examples recently included in the CPT code set that are assistive and augmentative services |
| 61 | Vaccine Early Release Policy Revision | | Review/revise the policy for early release/effective dates for vaccines and toxoids |

Updated April 28, 2023



| Tab# | Name | Code # | Request-Description |
|------|--|--------|--|
| | | | |
| 62 | TERMINATED | | |
| | | | |
| 63 | CCA Revisions Related to Digital Medicine/AI | | Request to add questions regarding AI to the CPT Code Change Application |
| | | | |